“Metastatic Breast Cancer Pipeline”
As per DelveInsight’s assessment, globally, Metastatic Breast Cancer pipeline constitutes 100+ key companies continuously working towards developing 100+ Metastatic Breast Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Metastatic Breast Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
“Metastatic Breast Cancer Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Metastatic Breast Cancer Market.
Some of the key takeaways from the Metastatic Breast Cancer Pipeline Report:
- Metastatic Breast Cancer Companies across the globe are diligently working toward developing novel Metastatic Breast Cancer treatment therapies with a considerable amount of success over the years.
- Metastatic Breast Cancer companies working in the treatment market are Phoenix Molecular Designs, Dantari, Inc., Daiichi Sankyo Co., Ltd., Rhizen Pharmaceuticals SA, Olema Oncology, Immutep S.A.S, Jiangsu HengRui Medicine Co., Ltd., Genor Biopharma Co., Ltd, RemeGen, SynCore Biotechnology, Byondis B.V., Sichuan Baili Pharmaceutical Co., Ltd., Allarity Therapeutics, Jiangsu Hansoh Pharmaceutical Co., Ltd., Kind Pharmaceuticals LLC, Shanghai Miracogen Inc., and others, are developing therapies for the Metastatic Breast Cancer treatment
- Emerging Metastatic Breast Cancer therapies in the different phases of clinical trials are- PMD-026, DAN-222, Patritumab Deruxtecan, Tenalisib, OP-1250, Eftilagimod alpha, SHR-A1811, GB491+ Fulvestrant, Disitamab Vedotin, EndoTAG®-1 (SB05), trastuzumab duocarmazine, Byondis B.V., Stenoparib (2X-121), HS-10342, AND019, MRG002, and others are expected to have a significant impact on the Metastatic Breast Cancer market in the coming years.
- On May 04, 2022, At the ESMO Breast Cancer Meeting, which will take place in Berlin, Germany from May 3–5, 2022, Rhizen Pharmaceuticals AG revealed that it will be presenting encouraging preliminary findings from a Ph2 trial of Tenalisib that is now underway in patients with locally advanced or metastatic breast cancer. In patients with main and secondary resistant mBC, tenalisib was well tolerated and had good preliminary efficacy as a single treatment; the data supports the further development of tenalisib in these individuals.
- In April 2022, Alphamab Oncology announced that at the AACR Annual Meeting 2022 (AACR 2022) an E-poster containing data from the phase II clinical investigation of the chemo-free regimen of KN026 in conjunction with KN046 (KN026-203) was presented. HER2-positive other solid tumors (non-breast cancer/gastric cancer) with ≥1L prior systemic therapy were enrolled in 24 patients as of August 10, 2021. Of these, 20 patients were evaluable for overall response, with an ORR of 55.0%, DCR of 85.0%, and 6-month PFS rate of 84.1%; of the 11 evaluable CRC patients, the ORR and DCR were 45.5% and 90.9%, respectively.
- In April 2022, The HER2-positive breast cancer treatment arm in the I-SPY 2.2 TRIAL has chosen Ambrx’s antibody-drug conjugate (ADC), ARX788, for neoadjuvant treatment. This announcement was made by Quantum Leap Healthcare CollaborativeTM (Quantum Leap) and Ambrx Biopharma Inc. The I-SPY 2.2 TRIAL, funded by Quantum Leap, is an extension of the I-SPY 2 TRIAL that aims to optimize the clinical outcome by customizing medicines for every patient.
- In March 2022, The Georgetown University researchers that submitted the poster abstract, “SM-88, D/L-alpha-metyrosine, is a novel anti-cancer agent in estrogen receptor-positive breast cancer,” have made it available, according to TYME Technologies, Inc. The abstract was given at the 2022 Annual Meeting of the American Association for Cancer Research (AACR) in New Orleans, Louisiana. The Phase II OASIS trial, which is being conducted by Georgetown University (NCT04720664) at several MedStar Health hospitals, is for patients with metastatic hormone receptor-positive, human epidermal growth factor receptor 2 negative (“HR+/HER2-“) breast cancer who have previously received a CDK4/6 inhibitor regimen. TYME Technologies, Inc. announced in September 2021 that the first patient had been dosed in this trial. Georgetown’s academic clinical partner is MedStar Health.
- In February 2022, In their Phase 1b monotherapy clinical trial, Phoenix Molecular Designs (PhoenixMD) has stated that patient recruitment and PMD-026 dosing are now complete. PhoenixMD has made significant progress toward moving PMD-026 into Phase 2 combo trials for triple-negative breast cancer (TNBC) and hormone-positive breast cancer with the successful completion of patient enrollment in this Phase 1/1b trial.
- In December 2021, A new PROTAC® estrogen receptor (ER) degrader, ARV-471, is being co-developed by Arvinas, Inc. and Pfizer Inc. to treat patients with locally advanced or metastatic ER-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer (ER+/HER2-). The companies recently released Phase 1 dose-escalation data.
- In August 2021, Disitamab vedotin is a new ADC that targets the HER2 receptor. Seagen Inc. and RemeGen Co., Ltd. announced that they have entered into an exclusive worldwide licensing deal to develop and market the drug.
Metastatic Breast Cancer Overview
When breast cancer spreads to another area of the body, usually the brain, liver, lungs, or bones, it is referred to as metastatic breast cancer, also known as stage IV breast cancer. Many months or years after the initial diagnosis and treatment, breast cancer may recur in a different place of the body.
Get a Free Sample PDF Report to know more about Metastatic Breast Cancer Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/metastatic-breast-cancer-pipeline-insight
Emerging Metastatic Breast Cancer Drugs Under Different Phases of Clinical Development Include:
- PMD-026: Phoenix Molecular Designs
- DAN-222: Dantari, Inc.
- Patritumab Deruxtecan: Daiichi Sankyo Co., Ltd.
- Tenalisib: Rhizen Pharmaceuticals SA
- OP-1250: Olema Oncology
- Eftilagimod alpha: Immutep S.A.S
- SHR-A1811: Jiangsu HengRui Medicine Co., Ltd.
- GB491+ Fulvestrant: Genor Biopharma Co., Ltd
- Disitamab Vedotin: RemeGen
- EndoTAG®-1 (SB05): SynCore Biotechnology
- trastuzumab duocarmazine: Byondis B.V.
- Byondis B.V.: Sichuan Baili Pharmaceutical Co., Ltd.
- Stenoparib (2X-121): Allarity Therapeutics
- HS-10342: Jiangsu Hansoh Pharmaceutical Co., Ltd.
- AND019: Kind Pharmaceuticals LLC
- MRG002: Shanghai Miracogen Inc.
Metastatic Breast Cancer Route of Administration
Metastatic Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
Metastatic Breast Cancer Molecule Type
Metastatic Breast Cancer Products have been categorized under various Molecule types, such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Metastatic Breast Cancer Pipeline Therapeutics Assessment
- Metastatic Breast Cancer Assessment by Product Type
- Metastatic Breast Cancer By Stage and Product Type
- Metastatic Breast Cancer Assessment by Route of Administration
- Metastatic Breast Cancer By Stage and Route of Administration
- Metastatic Breast Cancer Assessment by Molecule Type
- Metastatic Breast Cancer by Stage and Molecule Type
DelveInsight’s Metastatic Breast Cancer Report covers around 100+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Further Metastatic Breast Cancer product details are provided in the report. Download the Metastatic Breast Cancer pipeline report to learn more about the emerging Metastatic Breast Cancer therapies
Some of the key companies in the Metastatic Breast Cancer Therapeutics Market include:
Key companies developing therapies for Metastatic Breast Cancer are – Sun Pharmaceutical Industries Ltd., F. Hoffmann-La Roche AG, Bayer AG, Bristol-Myers Squibb Company, Boehringer Ingelheim Gmbh, Applied Molecular Genetics Inc., and Aslan Pharmaceuticals Pte. Ltd., and others.
Metastatic Breast Cancer Pipeline Analysis:
The Metastatic Breast Cancer pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Metastatic Breast Cancer with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Metastatic Breast Cancer Treatment.
- Metastatic Breast Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Metastatic Breast Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Metastatic Breast Cancer market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Metastatic Breast Cancer drugs and therapies
Metastatic Breast Cancer Pipeline Market Drivers
Increasing prevalence of breast cancer, launch of several diagnostic and screening programs are some of the important factors that are fueling the Metastatic Breast Cancer Market.
Metastatic Breast Cancer Pipeline Market Barriers
However, high cost associated with the treatment, several side effects associated with the use of breast cancer therapeutics and other factors are creating obstacles in the Metastatic Breast Cancer Market growth.
Scope of Metastatic Breast Cancer Pipeline Drug Insight
- Coverage: Global
- Key Metastatic Breast Cancer Companies: Phoenix Molecular Designs, Dantari, Inc., Daiichi Sankyo Co., Ltd., Rhizen Pharmaceuticals SA, Olema Oncology, Immutep S.A.S, Jiangsu HengRui Medicine Co., Ltd., Genor Biopharma Co., Ltd, RemeGen, SynCore Biotechnology, Byondis B.V., Sichuan Baili Pharmaceutical Co., Ltd., Allarity Therapeutics, Jiangsu Hansoh Pharmaceutical Co., Ltd., Kind Pharmaceuticals LLC, Shanghai Miracogen Inc., and others
- Key Metastatic Breast Cancer Therapies: PMD-026, DAN-222, Patritumab Deruxtecan, Tenalisib, OP-1250, Eftilagimod alpha, SHR-A1811, GB491+ Fulvestrant, Disitamab Vedotin, EndoTAG®-1 (SB05), trastuzumab duocarmazine, Byondis B.V., Stenoparib (2X-121), HS-10342, AND019, MRG002, and others
- Metastatic Breast Cancer Therapeutic Assessment: Metastatic Breast Cancer current marketed and Metastatic Breast Cancer emerging therapies
- Metastatic Breast Cancer Market Dynamics: Metastatic Breast Cancer market drivers and Metastatic Breast Cancer market barriers
Request for Sample PDF Report for Metastatic Breast Cancer Pipeline Assessment and clinical trials
Table of Contents
1. Metastatic Breast Cancer Report Introduction
2. Metastatic Breast Cancer Executive Summary
3. Metastatic Breast Cancer Overview
4. Metastatic Breast Cancer- Analytical Perspective In-depth Commercial Assessment
5. Metastatic Breast Cancer Pipeline Therapeutics
6. Metastatic Breast Cancer Late Stage Products (Phase II/III)
7. Metastatic Breast Cancer Mid Stage Products (Phase II)
8. Metastatic Breast Cancer Early Stage Products (Phase I)
9. Metastatic Breast Cancer Preclinical Stage Products
10. Metastatic Breast Cancer Therapeutics Assessment
11. Metastatic Breast Cancer Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Metastatic Breast Cancer Key Companies
14. Metastatic Breast Cancer Key Products
15. Metastatic Breast Cancer Unmet Needs
16 . Metastatic Breast Cancer Market Drivers and Barriers
17. Metastatic Breast Cancer Future Perspectives and Conclusion
18. Metastatic Breast Cancer Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting-services
Press Release Distributed by ABNewswire.com
To view the original version on ABNewswire visit: Metastatic Breast Cancer Pipeline Report (2024 Updates): FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Phoenix Molecular, Daiichi Sankyo, Rhizen Pharmaceuticals, Olema Oncology
